Prevention of aHUS involves:
This is for informational purposes only. For medical advice or diagnosis, consult a professional. AI responses may include mistakes. Learn more
[Generated for Academic Use] Date: April 13, 2026 atypical hemolytic syndrome
This continuous attack leads to systemic thrombotic microangiopathy (TMA). TMA causes tiny blood clots to form, which obstruct blood flow and damage vital organs. While the kidneys are usually the primary target, aHUS can affect the brain, heart, lungs, and gastrointestinal tract. Symptoms and Clinical Presentation
Diagnosing aHUS is often difficult because it mimics other conditions, such as Thrombotic Thrombocytopenic Purpura (TTP) or Shiga toxin-producing E. coli HUS (STEC-HUS). Doctors typically reach an aHUS diagnosis by "exclusion," ruling out other causes of TMA through blood tests and genetic screening. Treatment Evolution: From Plasma to Biologics Prevention of aHUS involves: This is for informational
The diagnosis of aHUS is based on the following criteria:
Long-term safety of C5 inhibition is unclear. Limited data suggest some patients (especially those with MCP mutations or anti-FH antibodies that remit) may discontinue after sustained remission >12-24 months. However, 20-30% relapse upon discontinuation, sometimes with irreversible renal loss. Decision requires shared decision-making and close monitoring. Learn more [Generated for Academic Use] Date: April
Background. Atypical hemolytic uremic syndrome (aHUS) is a rare and heterogeneous disorder. The first line treatment of aHUS is pl... PubMed Central (PMC) (.gov) Atypical Hemolytic Uremic Syndrome: Differential Diagnosis ... - PMC INTRODUCTION * Hemolytic uremic syndrome (HUS) is a rare and severe thrombotic microangiopathy (TMA) characterized by the triad of... PubMed Central (PMC) (.gov) Overcoming technical challenges when treating atypical hemolytic ... Introduction. Hemolytic uremic syndrome (HUS) is a hematological disease characterized mainly by the triad of microangiopathic hem... PubMed Central (PMC) (.gov) HUS and atypical HUS - PMC Among the 30% to 50% of patients with HUS who have no detectable complement defect, some have either impaired diacylglycerol kinas... PubMed Central (PMC) (.gov) Atypical Hemolytic Uremic Syndrome: Causes, Symptoms, and Treatment Oct 3, 2024 —
Advancements in genetic testing have made it easier to identify specific mutations, helping families understand their risks. While aHUS remains a complex and challenging diagnosis, modern medicine has significantly improved survival rates and quality of life for those affected.
Unlike STEC-HUS, aHUS is often preceded by non-diarrheal triggers: upper respiratory infection (Streptococcus pneumoniae, influenza), pregnancy (post-partum aHUS), malignancy, solid organ or stem cell transplant, and certain medications (calcineurin inhibitors, chemotherapy).